Investor Presentation
Investor Presentation
Brisbane, Sep 27, 2017 AEST (ABN Newswire) - Oventus Medical Ltd (ASX:OVN) provide the latest Investor Presentation.

Oventus - investment highlights

1. Oventus is driving the most significant change the sleep apnoea market has seen for years

2. Two key product ranges, both of which are set to disrupt a large and growing market:

OzVent Airway Technology oral appliance - currently generating revenue

CPAP machine* connector to 02Vent- in late stage development (replaces face mask)

3. Agreement executed in June 2017 with world's largest dental prosthetics supplier, Modern Dental Group. Oventus and Modern now preparing for Modern to distribute Oventus' range globally through their established channels

4. Obstructive Sleep Apnoea (OSA) is a massive market. US$3.8b globally, growing at a CAGR of 15-20% with only 20% of OSA sufferers in care

5. Strong institutional investor interest and solid balance sheet with $8.6m in cash (as at 30/6/17)

* CPAP machine: continuous positive airway pressure machine.

To view the presentation, please visit:
http://abnnewswire.net/lnk/0L6QT92E


About Oventus Medical Ltd

Oventus Medical Ltd (ASX:OVN) is a Brisbane, Australia, based medical device company that is commercialising a new 'Sleep Treatment Platform' for the treatment of sleep apnoea and snoring. The Oventus platform enhances the treatment outcomes of both standard mouthguard-type oral appliance therapy (often used to treat mild to moderate sleep apnoea) and of Continuous Positive Airway Pressure (CPAP) therapy (often used to treat moderate to severe patients.)

Since the Oventus 'Sleep Treatment Platform' is generally well tolerated by patients, and incorporates a unique airway, which supports better breathing, it has been shown in clinical trials to have increased efficacy and provide greater adherence over the competing treatment options.

For more information on Oventus' Sleep Treatment Platform, please visit http://www.oventus.com

      


Contact

Mr Neil Anderson
Managing Director and CEO
M: 0403 003 475

Kyahn Williamson
WE Buchan
P: 03 9866 4722 or kwilliamson@buchanwe.com.au



Related Companies

Oventus Medical Ltd

ABN Newswire This Page Viewed:  (Last 7 Days: 31) (Last 30 Days: 166) (Since Published: 4260) 
ANALYTICS: LOGIN HERE

Oventus Medical Ltd NEWS: RECENT VISITS (4818)